ReviewNPJ vaccines2021
Looking beyond meningococcal B with the 4CMenB vaccine: the Neisseria effect.
Review in NPJ vaccines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Defining the Efficacy of Meningococcal B Vaccines Against Gonococcal Acquisition: The Current Landscape.Journal of the International AIDS Society · 2026Review
- Modeling the Public Health Impact of Introducing 4CMenB Vaccination for Infants in the Brazilian National Immunization Program.Infectious diseases and therapy · 2026Article
- Pharmaceutical design of mRNA vaccines for endemic infectious diseases: integrating antigen discovery with platform engineering.Clinical and experimental vaccine research · 2026Review
- Post-marketing safety profile of meningococcal group B vaccines: a real-world disproportionality analysis of the VAERS database, 2015Q1-2025Q3.Frontiers in pharmacology · 2026Article
- Bacterial Foreignization Nanosystem Elicits Multi-Phenotypic T Cells for Antitumor Immunity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Correlates of Meningococcal B Vaccination and Health Behavior Profiles Among MSM in China.Vaccines · 2025Article
- Global burden of female infertility attributable to sexually transmitted infections and maternal sepsis: 1990-2021 and projections to 2050.Scientific reports · 2025Article
- Management and prevention of Neisseria meningitidis and Neisseria gonorrhoeae infections in the context of evolving antimicrobial resistance trends.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Review
- Biomimetic strategies of cell membrane vesicles driven by pathogen-host interactions: novel insights into antimicrobial immunotherapy and infection prevention.Frontiers in immunology · 2025Review
- Current methods in the diagnosis of invasive meningococcal disease.Frontiers in pediatrics · 2025Review
- Isolation of human monoclonal antibodies from 4CMenB vaccinees reveals PorB and LOS as the main OMV components inducing cross-strain protection.Frontiers in immunology · 2025Article
- 4CMenB journey to the 10-year anniversary and beyond.Human vaccines & immunotherapeutics · 2024Review
- Development of High-Production Bacterial Biomimetic Vesicles for Inducing Mucosal Immunity Against Avian PathogenicInternational journal of molecular sciences · 2024Article
- Urgent Need to Understand and Prevent Gonococcal Infection: From the Laboratory to Real-World Context.The Journal of infectious diseases · 2024Review
- Meningococcal meningitis in Spain in the Horizon 2030: A position paper.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2024Review
- Immunity to Sexually Transmitted Bacterial Infections of the Female Genital Tract: Toward Effective Vaccines.Vaccines · 2024Review
- Children with perinatally acquired HIV exhibit distinct immune responses to 4CMenB vaccine.JCI insight · 2024Article
- Review
- The genomic epidemiology ofThe Lancet regional health. Western Pacific · 2024Article
- The overlooked bacterial pandemic.Seminars in immunopathology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infections with Neisseria meningitidis and Neisseria gonorrhoeae have different clinical manifestations, but the bacteria share up to 80-90% genome sequence identity. The recombinant meningococcal serogroup B (MenB) vaccine 4CMenB consists of four antigenic components that can be present in non-B meningococcal and gonococcal strains. This comprehensive review summarizes scientific evidence on the genotypic and phenotypic similarities between vaccine antigens and their homologs expressed by non-B meningococcal and gonococcal strains. It also includes immune responses of 4CMenB-vaccinated individuals and effectiveness and impact of 4CMenB against these strains. Varying degrees of strain coverage were estimated depending on the non-B meningococcal serogroup and antigenic repertoire. 4CMenB elicits immune responses against non-B meningococcal serogroups and N. gonorrhoeae. Real-world evidence showed risk reductions of 69% for meningococcal serogroup W clonal complex 11 disease and 40% for gonorrhea after 4CMenB immunization. In conclusion, functional antibody activity and real-world evidence indicate that 4CMenB has the potential to provide some protection beyond MenB disease.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.